/
ICLR
$176.91+$3.20 (+1.84%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$13.3B
77M shares
52-week range
$66.57 – $211.00
76% from low
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-38.17
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.60B | $2.81B | $2.80B | $5.48B | $7.74B | $8.12B | $8.28B | $8.25B |
| Cost of revenue | $1.83B | $1.97B | $1.99B | $3.97B | $5.53B | $5.72B | $5.85B | $6.08B |
| Gross profit | $769.5M | $831.7M | $808.0M | $1.51B | $2.21B | $2.40B | $2.44B | $2.18B |
| Gross margin | 29.6% | 29.6% | 28.9% | 27.5% | 28.6% | 29.6% | 29.4% | 26.4% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $373.4M | $433.4M | $391.5M | $378.5M | $795.2M | $956.2M | $1.10B | $1.01B |
| EBITDA | $451.8M | $532.2M | $488.8M | $739.4M | $1.41B | $1.52B | $1.56B | $823.6M |
| Net income | $322.8M | $374.0M | $327.8M | $153.2M | $505.3M | $612.3M | $791.5M | $229.3M |
| Net margin | 12.4% | 13.3% | 11.7% | 2.8% | 6.5% | 7.5% | 9.6% | 2.8% |
| EPS (diluted) | 5.90 | 6.79 | 6.24 | 2.25 | 6.13 | 7.40 | 9.53 | 2.90 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8.0B | $10.62 | $10.39–$10.79 | 10 |
| 2027 | $8.3B | $11.89 | $11.19–$12.77 | 10 |
| 2028 | $8.7B | $13.36 | $11.41–$16.03 | 6 |
| 2029 | $9.1B | $15.58 | $15.38–$15.78 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$193.61
Price
$176.91
Implied upside
+9%
Peer comparison
Icon Plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
www.iconplc.com- Employees
- 40,100
- IPO / List date
- May 15, 1998
Held by traders on TradeandTell
No one on the platform currently holds ICLR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ICLR as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ICLR yet.
